Non-interventional Study (NIS) in Patients With Restless Legs Syndrome in Daily Practise

• Status: Completed
• Trial end date: 2011-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This non-interventional observational study is designed to gain data for Neupro® in restless legs syndrome (RLS) under real life conditions in line with the summary of product characteristics (SmPC) related to effectiveness, tolerability and switching practice from other dopaminergic drugs as well as titration schemes.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: UCB Pharma
• Treatments: N 0437; Rotigotine

Criteria

Inclusion Criteria:

• It was recommended that the patient's treatment was in accordance with the local marketing authorization (MA) for Neupro®

• The patient must have a diagnosis of moderate to severe idiopathic RLS

• The patient is considered reliable and capable of adhering to the visit schedule or medication administration according to the judgment of the investigator

• The decision to prescribe the drug has been made by the physician independently of his/her decision to include the patient in the study

• Subject is informed and given ample time and opportunity to think about his/her participation in the study and has given written informed data consent

Exclusion Criteria:

• Hypersensitivity to the active substance or to any of the excipients

• Magnetic resonance imaging or cardioversion (see SmPC)